{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:47:14Z","timestamp":1761763634795},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1023\/a:1008332724977","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:41:38Z","timestamp":1040550098000},"page":"183-188","source":"Crossref","is-referenced-by-count":34,"title":["Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"R.","family":"Morant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Borner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Fey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jacky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Trinkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hanselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"H\u00fcrny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Hering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008332724977_bb0005","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1056\/NEJM199410133311507","article-title":"Management of cancer of the prostate","volume":"331","author":"Catalona","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1008332724977_bb0010","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.1997.15.9.3156","article-title":"Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer","volume":"15","author":"Hudes","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0090-4295(97)00323-3","article-title":"Oral estramustine and oral etoposide for hormone-refractory prostate cancer","volume":"50","author":"Dimopooulos","year":"1997","journal-title":"Urology"},{"key":"10.1023\/A:1008332724977_bb0020","first-page":"15","article-title":"Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer","volume":"24","author":"Pienta","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008332724977_bb0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0094-0143(05)70390-6","article-title":"The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone-refractory prostate cancer","volume":"24","author":"Smith","year":"1997","journal-title":"Urol Clin North"},{"key":"10.1023\/A:1008332724977_bb0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.1993.11.4.596","article-title":"Serum prostate-specific antigen: Expanding its role as a measure of treatment response in patients with prostate cancer","volume":"11","author":"Andriole","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0035","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.1993.11.4.607","article-title":"Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","volume":"11","author":"Kelly","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0040","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0959-8049(97)00187-1","article-title":"Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG)","volume":"33","author":"Curran","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008332724977_bb0045","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1985.3.7.1013","article-title":"Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate","volume":"3","author":"Tannock","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0050","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1994.12.4.689","article-title":"Use of palliative end points to evaluate the effects of Mitoxantrone and low-dose Prednisone in patients with hormonally resistant prostate cancer","volume":"12","author":"Moore","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0060","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0065","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s005200050195","article-title":"Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK)","volume":"6","author":"Jungi","year":"1998","journal-title":"Support Care Cancer"},{"key":"10.1023\/A:1008332724977_bb0070","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/(SICI)1097-0142(19970501)79:9<1703::AID-CNCR10>3.0.CO;2-1","article-title":"A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research","volume":"79","author":"Schmid","year":"1997","journal-title":"Cancer"},{"key":"10.1023\/A:1008332724977_bb0075","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1023\/A:1008332724977_bb0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0045(199603)28:3<172::AID-PROS4>3.0.CO;2-H","article-title":"Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells","volume":"28","author":"Cronauer","year":"1996","journal-title":"Prostate"},{"key":"10.1023\/A:1008332724977_bb0085","first-page":"A1109","article-title":"Gemcitabine in hormone-refractory metastatic prostatic carcinoma: A phase II study of the SAKK","volume":"16","author":"Morant","year":"1997","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0090","first-page":"A1301","article-title":"for the Swiss Group for Clinical Cancer Research (SAKK). Quality of life in a phase II trial of Gemcitabine in hormone-refractory metastatic prostatic carcinoma","volume":"17","author":"Morant","year":"1998","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"10.1023\/A:1008332724977_bb0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-hfe instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008332724977_bb0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00366447","article-title":"The perceived adjustment to chronic illness scale (PACIS) A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG)","volume":"1","author":"H\u00fcrny","year":"1993","journal-title":"Support Care Cancer"},{"key":"10.1023\/A:1008332724977_bb0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnarie QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1023\/A:1008332724977_bb0110","first-page":"A1248","article-title":"Relationship between changes in serum prostatic specific antigen (PSA) and palliative response following treatment of symptomatic hormone-refractory prostate cancer (HRPC)","volume":"17","author":"Dowling","year":"1998","journal-title":"Proc Annu Meet Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341954902X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341954902X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/2\/183\/19478200\/11-2-183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:13:43Z","timestamp":1582164823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341954902X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["S092375341954902X"],"URL":"https:\/\/doi.org\/10.1023\/a:1008332724977","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}